Johnson & Johnson $JNJ Stock Bought by Colton Groome Financial Advisors LLC

Colton Groome Financial Advisors LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 219.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,145 shares of the company’s stock after purchasing an additional 4,906 shares during the quarter. Colton Groome Financial Advisors LLC’s holdings in Johnson & Johnson were worth $1,892,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Outlook Capital Management LLC purchased a new position in shares of Johnson & Johnson during the 2nd quarter valued at approximately $28,000. Matrix Trust Co boosted its stake in shares of Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after acquiring an additional 54 shares in the last quarter. Hyposwiss Advisors SA acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $42,000. Montgomery Financial Services LLC acquired a new position in Johnson & Johnson in the 2nd quarter worth about $43,000. Finally, Polaris Financial Partners acquired a new position in Johnson & Johnson in the 3rd quarter worth about $56,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer Taubert sold 15,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. This represents a 48.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 87,569 shares of company stock valued at $23,064,544 in the last quarter. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on JNJ. Wells Fargo & Company upped their target price on Johnson & Johnson from $272.00 to $282.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Bank of America reissued a “neutral” rating and issued a $278.00 price target on shares of Johnson & Johnson in a report on Tuesday, September 29th. Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a research report on Monday, August 3rd. TD Cowen lifted their target price on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $276.22.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson’s diversified pharmaceutical, medical-device and consumer-health businesses, along with new drug launches and sales growth, give it an advantage over Pfizer despite Pfizer’s lower valuation and higher dividend yield. Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
• Positive Sentiment: Analysts and financial commentators continue to view J&J as a defensive dividend holding: demand for healthcare products may remain resilient during an economic downturn, supporting its long record of dividend increases. Looking for a Dividend Stock That Can Weather a Downturn?
• Neutral Sentiment: J&J and Procter & Gamble trade at similar valuations, with the investment comparison centered on which company can sustain dividend growth over the next two decades. The discussion supports J&J’s income-investment appeal but does not introduce a new company-specific catalyst. Johnson & Johnson or Procter & Gamble
• Neutral Sentiment: Johnson & Johnson is expected to report earnings on October 13. Although earnings are projected to grow, one analysis says the company lacks the usual combination of estimate revisions and other factors associated with a likely earnings beat, potentially limiting pre-earnings optimism. Johnson & Johnson Earnings Expected to Grow
• Negative Sentiment: Investors remain concerned that a roughly $4 billion revenue patent cliff in 2027 could pressure growth. The key issue is whether J&J’s replacement pipeline and new launches can offset the loss of exclusivity, making the upcoming earnings report more important than the quarterly EPS result alone. Why a $4 Billion 2027 Patent Cliff Matters

Johnson & Johnson Price Performance

JNJ traded up $1.62 on Tuesday, reaching $254.55. 2,347,308 shares of the company’s stock were exchanged, compared to its average volume of 7,977,202. Johnson & Johnson has a twelve month low of $182.94 and a twelve month high of $281.07. The stock has a market cap of $613.44 billion, a PE ratio of 29.49, a P/E/G ratio of 2.52 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The stock’s fifty day moving average price is $266.10 and its 200-day moving average price is $248.51.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business’s revenue was up 6.6% on a year-over-year basis. During the same period last year, the company posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Sell-side analysts expect that Johnson & Johnson will post 11.54 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s payout ratio is 62.11%.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.